• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

Nervianos Aurora kinase effective and safe in Phase I

Posted on October 23, 2008 by crimsoncanary

Data presented at the EORTC-NCI-AACR Symposium show Nerviano’s Aurora kinase inhibitor PHA 739358 to demonstrate good tolerability early signs of efficacy

Filed under: Uncategorized | Tagged: aurora, kinase, nerviano, PHA-739358, PHA739358

« GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184 Please update your bookmarks »
  • Calendar

    • October 2008
      M T W T F S S
      « Sep    
       12345
      6789101112
      13141516171819
      20212223242526
      2728293031  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer